Summary: The aim of workshop was to bring together a wide range of stakeholders to have an open- forum and use the collective intelligence in the room to provide concrete recommendations on how to improve national and international science-policy ecosystems.
“Policy making is messy and other stakeholders need to realize this and manage this..“ Rafael Bengoa, Former Minister for Health. Basque Government; Former Director Health Systems WHO, Spain.
Organisers: University of Geneva, Division of Tropical and Humanitarian Medicine, NCD Policy Lab, Geneva Science-Policy Interface
The workshop participants explored the pros and cons of screening and Teplizumab and identified cross-cutting themes that need to be addressed when thinking about its introduction.
Although screening for type 1 diabetes has been available for quite some time, until recently no therapeutic solutions were available for people identified at risk of developing this condition. The advent of Teplizumab marks a milestone for type 1 diabetes, however different factors need to be explored in order to develop appropriate responses as we transition from research settings for screening and the use of Teplizumab to implementation within health systems.